Comparing the current results to its competitors, Societal Cdmo Inc reported Revenue increase in the 4 quarter 2023 by 14.17 % year on year, while most of its competitors have experienced contraction in revenues by -5.15 %, achieved in the same quarter.
Societal Cdmo Inc , slower than the average decrease reported by the company's competitors of -14.34 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -14.34 %
Societal Cdmo Inc 's Comment on Competition and Industry Peers
The company operates in the contract development and manufacturing organization (CDMO) sector for pharmaceuticals, a highly competitive and regulated industry. Its competitors include Adare Pharma Solutions, Aenova Alcami, Avara Pharmaceutical Services, Corden Pharma, CoreRx, Pharmaceutics International, Quotient Sciences, and Recipharm. It also competes with divisions of larger companies such as Patheon, a segment of ThermoFisher Scientific, Lonza, and Catalent. Several competitors possess greater financial resources, larger workforces, and more extensive marketing and manufacturing capabilities.
Avid Bioservices Inc is a biopharmaceutical company that provides contract development and manufacturing services for the production of biologics, including antibodies and mammalian cell-based therapies, to pharmaceutical and biotechnology companies.
Corcept Therapeutics Inc operates using a business model that focuses primarily on the research, development, and commercialization of pharmaceutical products. The company aims to discover and develop medications for conditions related to cortisol dysregulation, with a specific focus on Cushing's syndrome and psychiatric disorders. Additionally, Corcept Therapeutics Inc aims to ensure the successful commercialization of their products through collaborations and partnerships with other organizations to reach a wider market.
Intellipharmaceutics International Inc Share Performance
+900.00%
One Year
Intellipharmaceutics International Inc
Profile
Intellipharmaceutics International Inc.'s business model involves the development and commercialization of novel controlled-release and targeted-release oral solid dosage drugs.
Catalent Incs business model centers around offering comprehensive development and delivery solutions to pharmaceutical, biotechnology, and consumer health companies. By providing a diverse array of services such as drug development, manufacturing, packaging, and supply chain management, they aim to expedite the market entry of innovative and life-saving products for their clients.
Thermo Fisher Scientific Inc operates as a global leader in scientific research and services by delivering an extensive range of high-quality scientific instruments, reagents, consumables, and software solutions tailored to industries such as healthcare, pharmaceuticals, biotechnology, academia, and government. The company enhances its value proposition through a comprehensive suite of services, including laboratory outsourcing, scientific consulting, and data analysis, which help streamline research and development processes for its customers. By leveraging advanced technology and deep industry expertise, Thermo Fisher empowers researchers and organizations to drive innovation and accelerate scientific discovery.
Sources:
Societal Cdmo Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Societal Cdmo Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
